

11 December 2020
EMA/109720/2020
Data Analytics and Methods Task Force

Agenda for “EU Big Data Stakeholder Forum”

15 December 2020,
Virtual meeting, European Medicines Agency



Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Objectives

- Inform on implementation of the HMA-EMA Big Data Task Force priority recommendations.
- Understand stakeholders' perspectives and priorities.
- Discuss opportunities for stakeholder collaboration.

Agenda details

Tuesday, 15 December 2020

08:30 Connection to virtual room and technical checks

09:00 Welcome and introduction

Emer Cooke, EMA 10'

Ioana-Maria Gligor, EC 10'

Thomas Senderovitz, DKMA 10'

09:30 Session 1: Implementation of the HMA-EMA Big Data Task Force priority recommendations

Chair: **Nikolai Brun**, DKMA

Summary of the HMA/EMA Big Data Taskforce priority recommendations and plan for implementation

Peter Arlett, EMA 30'

10:00 Session 2: Stakeholders' priorities

Chair: **Peter Arlett**, EMA

Aggregated feedback from pre-meeting survey
Francois Domergue, EMA 10'

Stakeholder perspective – Patients

Marilena Vrana, European Heart Network 10'

- **Priorities**
- **Opportunities/risks**
- **Area for collaboration/engagement**

Stakeholder perspective –Consumers

Jelena Malinina, The European Consumer Organisation 10'

- **Priorities**
- **Opportunities/risks**
- **Area for collaboration/engagement**

Stakeholder perspective –Doctors

Ioana Agache, European Academy of Allergy and Clinical Immunology 10'

- **Priorities**
- **Opportunities/risks**
- **Area for collaboration/engagement**

Stakeholder perspective –Pharmacists
John Yfantopoulos, University of Athens 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

Stakeholder perspective –Nurses
Maria-Teresa Parisotto, European Specialist Nurses Organisation 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

11:00 Break

11:30 Session 2: Stakeholders' priorities (cont.)

Stakeholder perspective - Pharmaceutical industry – EFPIA/EuropaBio
Álmath M. Spooner, AbbVie 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

Stakeholder perspective - Pharmaceutical industry – EUCOPE
Maren von Fritschen, EUCOPE 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

Stakeholder perspective - Pharmaceutical industry –Medicines for Europe/AESGP
Susana Almeida, Medicines for Europe / **Paul-Etienne Schaeffer**, AESGP 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

Stakeholder perspective - Medical Devices industry – MedTech
Michael Strübin, MedTech Europe 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

Stakeholder perspective –Researchers
Susana Perez-Gutthann, RTI Health Solutions 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

Stakeholder perspective – Academia
Laurence Collette, EORTC 10'
•Priorities
•Opportunities/risks
•Area for collaboration/engagement

12:30 **Break**

13:00 **Session 3: Discussion - making it happen**

Chair: **Nikolai Brun**, DKMA

Questions & Answers

10 questions circulated to the stakeholders

50'

13:50 **Concluding remarks (Discuss opportunities for stakeholder collaboration)**

Peter Arlett, EMA

10'

Vision and work planning, events 2021, likely consultations

14:00 **End of the meeting**

NOTE:

*At certain points throughout the discussions, the audience will be able to give their input on Sli.do. Participation in Sli.do is voluntary and represents agreement to the terms of use. During the Sli.do interaction you may opt to remain anonymous; for more information on data protection considerations that apply to the use of Sli.do please refer to their privacy policy on www.sli.do/terms#privacy-policy
Anonymous content data submitted by participants (questions asked, answers provided) will be processed and used for the stated purpose of the meeting by event organisers.
For more information on data protection considerations that apply to EMA meetings and events please refer to our privacy statement on www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-organisation-meetings-events_en.pdf*

